Marzio Dina L Halegoua-De, Fenkel Jonathan M
Dina L Halegoua-De Marzio, Jonathan M Fenkel, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA 19107, United States.
World J Hepatol. 2014 Jan 27;6(1):9-16. doi: 10.4254/wjh.v6.i1.9.
Chronic hepatitis C (CHC) infection affects almost 3% of the global population and can lead to cirrhosis, liver failure, and hepatocellular carcinoma in a significant number of those infected. Until recently, the only treatments available were pegylated interferon and ribavirin, which traditionally were not very effective and have considerable side effects. For this reason, interest in complementary and alternative medications (CAM) in the management of hepatitis C has been investigated. Some CAM has demonstrated therapeutic potential in chronic hepatitis C treatment. Unfortunately, some CAM has been shown to have the potential to cause drug-induced liver injury. This article will review and evaluate many of the natural molecules that interact with the hepatitis C virus (HCV) life cycle and discuss their potential use and safety in HCV therapy, as well as highlight some important interactions between medical and complementary treatments.
慢性丙型肝炎(CHC)感染影响着全球近3%的人口,在大量感染者中可导致肝硬化、肝衰竭和肝细胞癌。直到最近,可用的唯一治疗方法是聚乙二醇化干扰素和利巴韦林,传统上它们效果不太显著且有相当多的副作用。因此,人们对丙型肝炎管理中的补充和替代药物(CAM)进行了研究。一些CAM在慢性丙型肝炎治疗中已显示出治疗潜力。不幸的是,一些CAM已被证明有可能导致药物性肝损伤。本文将回顾和评估许多与丙型肝炎病毒(HCV)生命周期相互作用的天然分子,并讨论它们在HCV治疗中的潜在用途和安全性,同时强调医学治疗与补充治疗之间的一些重要相互作用。